Kadmon控股

KDMN NYSE
2.250
+0.010
+0.45%
已收盘, 16:51 05/22 EDT
开盘
2.210
昨收
2.240
最高
2.370
最低
2.210
成交量
92.07万
成交均量(3M)
81.91万
52周最高
4.390
52周最低
1.880
换手率
0.71%
市值
2.91亿
分时
5日
1月
3月
1年
5年

评论

暂无数据

相关股票

微牛行情栏目提供Kadmon控股 KDMN股票价格,Kadmon控股股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
展开 >

最近浏览

名称
价格
涨跌幅